These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 18793852

  • 1. Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
    Somsák L, Nagy V, Vidal S, Czifrák K, Berzsényi E, Praly JP.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5680-3. PubMed ID: 18793852
    [Abstract] [Full Text] [Related]

  • 2. Glucose-based spiro-heterocycles as potent inhibitors of glycogen phosphorylase.
    Nagy V, Benltifa M, Vidal S, Berzsényi E, Teilhet C, Czifrák K, Batta G, Docsa T, Gergely P, Somsák L, Praly JP.
    Bioorg Med Chem; 2009 Aug 01; 17(15):5696-707. PubMed ID: 19574053
    [Abstract] [Full Text] [Related]

  • 3. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 4. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 5. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 27; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 6. Glucopyranosylidene-spiro-benzo[ b][1,4]oxazinones and -benzo[ b][1,4]thiazinones: Synthesis and Investigation of Their Effects on Glycogen Phosphorylase and Plant Growth Inhibition.
    Kun S, Kánya N, Galó N, Páhi A, Mándi A, Kurtán T, Makleit P, Veres S, Sipos Á, Docsa T, Somsák L.
    J Agric Food Chem; 2019 Jun 19; 67(24):6884-6891. PubMed ID: 31135156
    [Abstract] [Full Text] [Related]

  • 7. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 8. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 Jul 01; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 9. Glucopyranosylidene-spiro-imidazolinones, a New Ring System: Synthesis and Evaluation as Glycogen Phosphorylase Inhibitors by Enzyme Kinetics and X-ray Crystallography.
    Szabó KE, Kyriakis E, Psarra AG, Karra AG, Sipos Á, Docsa T, Stravodimos GA, Katsidou E, Skamnaki VT, Liggri PGV, Zographos SE, Mándi A, Király SB, Kurtán T, Leonidas DD, Somsák L.
    J Med Chem; 2019 Jul 11; 62(13):6116-6136. PubMed ID: 31251604
    [Abstract] [Full Text] [Related]

  • 10. Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors.
    Birch AM, Kenny PW, Simpson I, Whittamore PR.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):850-3. PubMed ID: 19103484
    [Abstract] [Full Text] [Related]

  • 11. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly JP, Kizilis G, Tiraidis C, Alexacou KM, Chrysina ED, Zographos SE, Leonidas DD, Archontis G, Oikonomakos NG.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7368-80. PubMed ID: 19781947
    [Abstract] [Full Text] [Related]

  • 12. Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase.
    Gimisis T.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1127-38. PubMed ID: 20716054
    [Abstract] [Full Text] [Related]

  • 13. Synthesis of C-xylopyranosyl- and xylopyranosylidene-spiro-heterocycles as potential inhibitors of glycogen phosphorylase.
    Somsák L, Bokor É, Czibere B, Czifrák K, Koppány C, Kulcsár L, Kun S, Szilágyi E, Tóth M, Docsa T, Gergely P.
    Carbohydr Res; 2014 Nov 18; 399():38-48. PubMed ID: 25081322
    [Abstract] [Full Text] [Related]

  • 14. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM, Hayes JM, Tiraidis C, Zographos SE, Leonidas DD, Chrysina ED, Archontis G, Oikonomakos NG, Paul JV, Varghese B, Loganathan D.
    Proteins; 2008 May 15; 71(3):1307-23. PubMed ID: 18041758
    [Abstract] [Full Text] [Related]

  • 15. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
    Habash M, Taha MO.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4746-71. PubMed ID: 21788139
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

  • 17. A facile regioselective synthesis of novel spiro-thioxanthene and spiro-xanthene-9',2-[1,3,4]thiadiazole derivatives as potential analgesic and anti-inflammatory agents.
    Hafez HN, Hegab MI, Ahmed-Farag IS, el-Gazzar AB.
    Bioorg Med Chem Lett; 2008 Aug 15; 18(16):4538-43. PubMed ID: 18667305
    [Abstract] [Full Text] [Related]

  • 18. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846
    [Abstract] [Full Text] [Related]

  • 19. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
    Wen X, Sun H, Liu J, Cheng K, Zhang P, Zhang L, Hao J, Zhang L, Ni P, Zographos SE, Leonidas DD, Alexacou KM, Gimisis T, Hayes JM, Oikonomakos NG.
    J Med Chem; 2008 Jun 26; 51(12):3540-54. PubMed ID: 18517260
    [Abstract] [Full Text] [Related]

  • 20. Insulin sensitivity is modified by a glycogen phosphorylase inhibitor: glucopyranosylidene-spiro-thiohydantoin in streptozotocin-induced diabetic rats.
    Docsa T, Marics B, Németh J, Hüse C, Somsák L, Gergely P, Peitl B.
    Curr Top Med Chem; 2015 Jun 26; 15(23):2390-4. PubMed ID: 26095241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.